<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37078278</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>21</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2167-9223</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>3-4</Issue><PubDate><Year>2023</Year><Month>May</Month></PubDate></JournalIssue><Title>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</Title><ISOAbbreviation>Amyotroph Lateral Scler Frontotemporal Degener</ISOAbbreviation></Journal><ArticleTitle>Yield of EEG features as markers of disease severity in amyotrophic lateral sclerosis: a pilot study.</ArticleTitle><Pagination><StartPage>295</StartPage><EndPage>303</EndPage><MedlinePgn>295-303</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21678421.2022.2152696</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To clarify the role of electroencephalography (EEG) as a promising marker of severity in amyotrophic lateral sclerosis (ALS). We characterized the brain spatio-temporal patterns activity at rest by means of both spectral band powers and EEG microstates and correlated these features with clinical scores.</AbstractText><AbstractText Label="METHODS">Eyes closed EEG was acquired in 15 patients with ALS and spectral band power was calculated in frequency bands, defined on the basis of individual alpha frequency (IAF): delta-theta band (1-7&#x2009;Hz); low alpha (IAF - 2&#x2009;Hz&#x2009;-&#x2009;IAF); high alpha (IAF&#x2009;-&#x2009;IAF + 2&#x2009;Hz); beta (13&#x2009;-&#x2009;25&#x2009;Hz). EEG microstate metrics (duration, occurrence, and coverage) were also evaluated. Spectral band powers and microstate metrics were correlated with several clinical scores of disabilities and disease progression. As a control group, 15 healthy volunteers were enrolled.</AbstractText><AbstractText Label="RESULTS">The beta-band power in motor/frontal regions was higher in patients with higher disease burden, negatively correlated with clinical severity scores and positively correlated with disease progression. Overall microstate duration was longer and microstate occurrence was lower in patients than in controls. Longer duration was correlated with a worse clinical status.</AbstractText><AbstractText Label="CONCLUSIONS">Our results showed that beta-band power and microstate metrics may be good candidates of disease severity in ALS. Increased beta and longer microstate duration in clinically worse patients suggest a possible impairment of both motor and non-motor network activities to fast modify their status. This can be interpreted as an attempt in ALS patients to compensate the disability but resulting in an ineffective and probably maladaptive behavior.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Notturno</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Unit of Neurology, "Floraspe Renzetti" Hospital, Lanciano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Croce</LastName><ForeName>Pierpaolo</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-7279-3052</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Imaging and Clinical Sciences, University "Gabriele d'Annunzio" of Chieti-Pescara, Chieti, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Behavioral Imaging and Neural Dynamics Center, University "Gabriele d'Annunzio" of Chieti-Pescara, Chieti, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ornello</LastName><ForeName>Raffaele</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-9501-4031</Identifier><AffiliationInfo><Affiliation>Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sacco</LastName><ForeName>Simona</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-0651-1939</Identifier><AffiliationInfo><Affiliation>Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zappasodi</LastName><ForeName>Filippo</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-4768-4687</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Imaging and Clinical Sciences, University "Gabriele d'Annunzio" of Chieti-Pescara, Chieti, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Behavioral Imaging and Neural Dynamics Center, University "Gabriele d'Annunzio" of Chieti-Pescara, Chieti, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Advanced Biomedical Technologies, University "Gabriele d'Annunzio" of Chieti-Pescara, Chieti, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Amyotroph Lateral Scler Frontotemporal Degener</MedlineTA><NlmUniqueID>101587185</NlmUniqueID><ISSNLinking>2167-8421</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="Y">Brain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004569" MajorTopicYN="N">Electroencephalography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062072" MajorTopicYN="N">Patient Acuity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Disease severity</Keyword><Keyword MajorTopicYN="N">EEG microstate</Keyword><Keyword MajorTopicYN="N">beta band</Keyword><Keyword MajorTopicYN="N">electrophysiological marker</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>21</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>20</Day><Hour>5</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37078278</ArticleId><ArticleId IdType="doi">10.1080/21678421.2022.2152696</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>